The long-term success of national efforts to reduce breast cancer incidence and mortality rests in part on the ability of Breast Cancer SPORE programs to attract and build the translational research careers of talented young faculty. Since 1992, the UNC Breast Cancer SPORE has used career development funds to promote the breast cancer research careers of selected investigators. The SPORE Career Development Program (CDP) both recruits externally and identifies internal faculty with interest in translational breast cancer research. The CDP then matches junior faculty with training offerings and senior mentors. We seek to enrich the field with our efforts to recruit qualified women and minorities as both participants and mentors in the program. During this funding cycle, 6 of the 12 faculty selected were women and 2 were minorities. Co-recruitment with departments across campus attracts exceptional talent to UNC and its Cancer Center. The SPORE CDP makes available extended training for junior faculty with an interactive group of respected and successful investigators who can influence and help build careers. The combination of an excellent talent pool and an effective training and mentoring program results in an elite cadre of breast cancer researchers whose work contributes to the national breast cancer effort. CDP participants'contributions include published research, funded grants focused on breast cancer, participation in collaborative breast cancer research, and, leadership in the SPORE program itself. Seven CDP alumni (Drs. Amos, Carey, Dees, DeMore, Millikan, Perou, and Troester) serve as co-leaders on the proposed projects and cores. As a result of the Breast Cancer SPORE, these investigators are now firmly established as translational breast cancer researchers with distinct interests, collaborations, and honors. They represent unmistakable evidence of the CDP's success. Over the next five years, the UNC Breast Cancer SPORE will continue to promote and develop careers in translational breast cancer research. We request SPORE support of $50,000 per year to combine with $50,000 in institutional funds to provide $100,000 in flexible funds for career development. The SPORE will use these funds to help recruit and develop junior faculty in translational breast cancer research. The SPORE leaders will continue to identify, recruit, and develop minority and women faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-21
Application #
8723752
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
21
Fiscal Year
2014
Total Cost
$42,524
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304

Showing the most recent 10 out of 598 publications